{"groups":[{"description":"0.015 mg/kg/dose of ALT-801","id":"FG000","title":"ALT-801 0.015 mg/kg/Dose"},{"description":"0.040 mg/kg/dose of ALT-801","id":"FG001","title":"ALT-801 0.040 mg/kg/ Dose"},{"description":"0.080 mg/kg/dose of ALT-801","id":"FG002","title":"ALT-801 0.080 mg/kg/Dose"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"6"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Between 08-2007 and 05-2009, 118 patients were consented and screened, 56 were Human leukocyte antigen (HLA)-A2 positive and had tumor specimens that were positive for target p53 (aa 264-272)/HLA-A\\*0201 complex. Thirty HLA-A2-positive patients with p53/HLA-A\\*0201 tumors either withdrew consent or did not meet other inclusion/exclusion criteria."}